Expands Use of MoleMate™ Technology Via Cancer Screening Clinics in UAE and Australia
MISSISSAUGA, ON, Nov. 14, 2011 /CNW/ - MedX Health Corp., (TSXV.MDX) a global leader in drug free, non-invasive low level laser light therapy
and light imaging systems, announced today that ScreenCancer AS has
signed a new distributor agreement to expand the use of the MoleMate™
technology as part of their MoleNavigator service and will now include
Australia in their operations along with their existing programs in
Europe and the U.S.
MedX Health acquired the worldwide assets of MoleMate in June 2011. This
unique skin imaging system is FDA, CE approved and now available for
sale in the US, European Union, Australia, and the UK. MoleMate uses a
hand-held device designed for office or clinic use that utilizes light
to view up to 2mm beneath suspicious moles in a pain free, non-invasive
manner, creating images for physicians to evaluate moles and lesions
often eliminating the need for skin biopsies resulting in less pain,
scarring, and expense. Physicians interested in learning more should
contact their local representative on the web at http://simsys-molemate.com.
"We are excited about our expanded agreement with ScreenCancer AS.
ScreenCancer's mission is about increasing cancer screening thereby
reducing the costs of advanced cancer treatment, and most importantly
saving lives through early cancer detection. This includes the use of
the MoleMate for the convenient evaluation by dermatologists of
patient-identified suspicious moles," stated Steve Guillen, President &
CEO at MedX Health Corp. Our distributor agreement with ScreenCancer AS
currently covers the North America, the UK, Europe, and now it further
expands into the UAE and Australia, the largest skin cancer market in
the world," stated Steve Guillen, President & CEO at MedX Health Corp.
The total initial expanded distributor agreement is valued at over
$190,000 CDN for 2011, and the expanded agreement runs through 2015.
The FDA approved and CE Marked MoleMate Skin Imaging Systems is a
significant advance in the early detection of potentially life
threatening moles and lesions. Before MoleMate, physicians had to rely
solely on their naked eye or in some cases scopes which can only see
the top or outside of the skin to make a diagnosis, and often had to
rely on a biopsy which was painful, and delayed the results, adding to
the patient's fear and anxiety. Now with the MoleMate's, non-invasive,
pain-free imaging, physicians are immediately provided with accurate
images within the skin showing the location and distribution of
pigment, blood, and collagen below a mole or lesion, allowing them to
immediately decide if it is benign, or that it may only require
freezing or another procedure much less painful and costly than a
"MoleMate gives you more information to base your judgment on.
Previously I may have looked at a mole and put off doing anything. In
one or two cases, when viewed through MoleMate they have been nastier
than I thought. Being able to review a patient's moles over time is
particularly useful. I would recommend MoleMate to GPs and skin
clinics." ― Dr. G. Campbell, New South Wales, Australia
MoleMate and the more robust system, SIMSYS, work with a hand-held
scanner along with a specially designed training CD. SIMSYS allows
image capture and storage as well as special features that can be used
in visualizing and comparing moles. SIMSYS will also support "mole
mapping" early in 2012. Mole mapping is a technique that physicians
use on certain patients with 50-100 or more moles where the entire
surface of the patient's skin is photographed to observe changes over
time and then suspicious moles can be monitored more closely or, if
MoleMate is easy to incorporate into exams, and is easy for physicians
to learn how to use via the 60-90 minute training CD, as documented in
a study with general practitioners, who significantly improved their
ability to more accurately identify suspicious moles and lesion.
US Launch Underway
MedX Health has a direct sales team of 30 associates in addition to 4
regional specialty Distributors calling on dermatologists and primary
care physicians representing a $1B market opportunity based on retail
prices between $5-$10K per system.
The website http://simsys-molemate.com contains additional information on MoleMate and SIMSYS, including
information on the technology behind these products, siascopy, as well
as product demos, and information on how other physicians have
integrated the skin cancer imaging system into their practice, as well
as information on the recently announced Innovator's Program, which
allows physicians a free 30-day trial of both MoleMate and SIMSYS.
MoleMate and SIMSYS will also be presented at the American Academy of
Dermatology's 70th Annual Meeting, March 16-22, 2012, in San Diego, California, the
world's largest, most comprehensive dermatologic educational event.
Work with MoleMate and SIMSYS at booth #1361.
The Most Common Form of Cancer in the US
The Skin Cancer Foundation states that skin cancer is the most common
form of cancer in the US. Each year there are more new cases of skin
cancer than the combined incidence of cancers of the breast, prostrate,
lung and colon.
There are several types of skin cancers. Nearly 13 million people in
the US are living with a history of non-melanoma skin cancer, typically
diagnosed as basal cell carcinoma or squamous cell carcinoma. 800,000
people in the US are living with a history of melanoma. The survival
rate for patients, whose melanoma is detected early, before the tumor
has penetrated the skin, is about 99 percent. The survival rate falls
to 15 percent for those with advanced disease.
Proctor & Gamble, LenioMed Ltd., and ScreenCancer AS are research and/or
commercial partners whose support and expanding use are helping fund
the expansion of the underlying technology, siascopy, into new consumer
and wound care markets.
About MedX Health Corp.
MedX acquired the worldwide assets of MoleMate in June 2011. MedX is a
twelve (12) year old Canadian company, headquartered in Mississauga,
Ontario (Toronto), and is a global leader in the design, manufacturing
and distribution of quality low level laser and light therapy
technologies for use in numerous medical settings, including
rehab/chiropractic, dental, wound care, and veterinary medicine,
providing patients with drug free and non-invasive treatment of tissue
damage and pain. MedX laser and light products are FDA approved,
Health Canada cleared, and CE Mark approved for use in North America as
well as the European Union. For a complete profile of MedX Health
Corp. and its products visit www.medxhealth.com.
About ScreenCancer, AS
ScreenCancer provides cancer screening management services to employers,
insurers and individuals including the MoleNavigator, a
teledermatology-based solution for the evaluation of suspicious moles.
In the U.S., ScreenCancer offers the ScreenCancer Navigator program for
increasing cancer screening rates. In Europe, ScreenCancer
additionally provides a panel of leading screening tests for several
major cancers with clinical follow-up by experts in the field. For more
information, please visit the company's web site at www.screencancer.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
This press release does not constitute an offer of any securities for
sale. This press release contains certain forward-looking statements
within the meaning of applicable Canadian securities legislation.
These forward-looking statements involve certain risks and
uncertainties that could cause actual results to differ, including,
without limitation, the company's limited operating history and history
of losses, the inability to successfully obtain further funding, the
inability to raise capital on terms acceptable to the company, the
inability to compete effectively in the marketplace, the inability to
complete the proposed acquisition and such other risks that could cause
the actual results to differ materially from those contained in the
company's projections or forward-looking statements. All
forward-looking statements in this press release are based on
information available to the company as of the date hereof, and the
company undertakes no obligation to update forward-looking statements
to reflect events or circumstances occurring after the date of this
SOURCE MedX Health Corp.
For further information:
President and Chief Executive Officer
MedX Health Corp. email@example.com
Phone: (905) 670-4428